Flatiron Health and Foundation Medicine have partnered to create a Clinico-Genomic Database (CGDB). This first-in-class, real-world data source integrates complex biomarkers from patient tumors, with longitudinal treatment and outcomes data captured from electronic health records (EHR).

The CGDB is regularly updated to include new patients, additional complex signatures, longitudinal updates for existing patients as they progress through their treatment journey.

**PATIENT POPULATION**

- **EHR data** on treatment and clinical outcomes, curated by Flatiron
- **Genomic analyses** of patient samples, along with complex signatures, by Foundation Medicine

**CONTINUALLY-GROWING LONGITUDINAL DATA**

- **50,000+** cancer patients and growing
- **Real-world** anonymized, research-grade database

Flatiron and Foundation Medicine are committed to the stringent protection of patient privacy. All data in the CGDB is strictly de-identified, and all data linking processes are HIPAA-compliant in order to safeguard patient data.
What data is in the CGDB?

COMPREHENSIVE GENOMIC PROFILING:
Foundation One® and Foundation Heme® next-generation sequencing testing of tumor samples
• All molecular alterations detected across 300+ genes
• Clinical interpretation and reported therapies
• Complex Genomic Signatures
  • Tumor Mutational Burden (TMB)
  • Microsatellite instability (MSI)
  • Somatic-Germline-Zygosity (SGZ)
  • Loss of Heterozygosity (LOH)
• Immunohistochemistry (PD-L1)

CLINICAL DATA:
Longitudinal patient-level EHR data
• Demographics, risk factors
• Chart-confirmed diagnosis
• Stage and histology
• Treatments received, including lines of therapy
• Real-world clinical outcomes, including survival, progression, and tumor response

How are cohorts defined?
• Tumor type: understand the clinico-genomic landscape across a disease
• Biomarker-based: characterize patient populations with specific alterations
• Study-specific: define a specific cohort of interest

What research activities are supported?
• Novel target discovery
• Clinical trial planning and design
• Outcomes research in biomarker-defined populations
• Genotype-guided label expansion for existing therapies
• Portfolio planning and acquisition strategy
• Companion diagnostic development

How will the CDGB grow?
• Growth in the Flatiron provider network
• Growth in use of Foundation Medicine next-generation sequencing
• Updates to clinical data from the EHR (e.g., patient follow-up time)
• Updates to variant annotations and genomic analyses

To learn more about the Clinico-Genomic Database, contact Foundation Medicine at biopharma@foundationmedicine.com.

Reference: